Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection | Zendy

Bjorn L. Herpers | Zendy; Bart J. M. Vlaminckx | Zendy; Olaf Burkhardt | Zendy; Harmjo Blom | Zendy; H. S. Biemond-Moeniralam | Zendy; Mathias W. Hornef | Zendy; Tobias Welte | Zendy; Ed J. Kuijper | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous Tigecycline as Adjunctive or Alternative Therapy for Severe RefractoryClostridium difficileInfection

Author(s) -

Bjorn L. Herpers,

Bart J. M. Vlaminckx,

Olaf Burkhardt,

Harmjo Blom,

H. S. Biemond-Moeniralam,

Mathias W. Hornef,

Tobias Welte,

Ed J. Kuijper

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/599224

Subject(s) - tigecycline , medicine , refractory (planetary science) , clostridium difficile , salvage therapy , adjunctive treatment , rescue therapy , surgery , intensive care medicine , antibiotics , chemotherapy , microbiology and biotechnology , physics , astrobiology , biology

Clostridium difficile infection (CDI) has become more refractory to standard therapy. We describe 4 patients with severe refractory CDI who were successfully treated with tigecycline. Symptoms improved within 1 week. No relapses were observed. This favorable outcome suggests that tigecycline might be a useful alternative for treating severe refractory CDI.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research